This phase II trial tests how well fluorouracil, oxaliplatin and leucovorin calcium (folinic acid) (FOLFOX) with botensilimab and balstilimab given before surgery (neoadjuvant) works in treating patients with rectal adenocarcinoma that has not spread to other parts of the body (localized). Currently, neoadjuvant therapy for rectal cancer includes chemotherapy and chemoradiation. Despite these aggressive treatments, only about half of patients achieve a complete clinical response. In fact, over half of rectal cancer patients go on to have surgery and often suffer post-surgery complications involving urine and bowel problems. Thus, there has been an increased focus on non-surgical treatments. Chemotherapy drugs, such as fluorouracil, oxaliplatin and leucovorin calcium, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as botensilimab and balstilimab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving neoadjuvant FOLFOX with botensilimab and balstilimab may improve the rate of complete response and decrease the need for surgery and radiation therapy in patients with localized rectal adenocarcinoma.

Start Date30 Jun 2025

Sponsor / Collaborator

City of Hope National Medical Center

[+1]

NCT06843551

/ Not yet recruitingPhase 2IIT

A Phase 2 Single Arm Trial of Stereotactic Body Radiation Therapy Followed by Dual Immune Checkpoint Inhibition for Patients With Metastatic Pancreatic Ductal Adenocarcinoma - The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation

The purpose of this study is to assess if radiation therapy (which uses high-energy radiation to damage or destroy cancer cells) combined with immune checkpoint inhibitors (medications that helps the body recognize and attack cancer cells) will be beneficial for patients with metastatic pancreatic ductal adenocarcinoma.

Start Date01 Jun 2025

Sponsor / Collaborator

University of Miami

[+1]

NCT06843434

/ RecruitingPhase 2IIT

A Phase II Study of Neoadjuvant Botensilimab and Balstilimab Immunotherapy for Mismatch Repair Proficient Rectal Adenocarcinoma

The purpose of this study is to find out whether the combination of botensilimab and balstilimab (BOT/BAL) is a safe and effective treatment that causes few or mild side effects for people with mismatch repair proficient (MMRp)/microsatellite stable (MSS) locally advanced rectal adenocarcinoma. The investigators will also find out whether BOT/BAL is an effective treatment when given in combination with standard chemotherapy.

Start Date20 Feb 2025

Sponsor / Collaborator

Memorial Sloan Kettering Cancer Center

[+1]

100 Clinical Results associated with Botensilimab

100 Translational Medicine associated with Botensilimab

100 Patents (Medical) associated with Botensilimab

437

Literatures (Medical) associated with Botensilimab

01 Feb 2025·IMMUNOLOGY AND CELL BIOLOGY

Exploring the dynamics of T‐cell responses: a combined approach using EdU incorporation and proliferation dye dilution assay

Article

Author: Freen‐van Heeren, Julian J ; Raaphorst, Hilde ; Turksma, Annelies W ; Saou, Latifa ; ten Brinke, Anja ; Lougheed, Sinéad ; Rensink, Irma ; van Kleef, Nadine D

Abstract:

Understanding antigen‐specific T‐cell responses is crucial for advancing immunotherapies and vaccine development. This study proposes a novel approach combining two complementary assays: the 5‐ethynyl‐2′‐deoxyuridine (EdU) incorporation assay (tracking proliferation over 0–48 h) and the VPD450 dye dilution assay (tracking proliferation over 4–6 days). Integrating these techniques provides additional insights into T‐cell proliferation kinetics. Both assays were independently optimized using anti‐CD3 and anti‐CD28 polyclonal T cell stimulation. 1 μM VPD450 is suitable for assessing T‐cell proliferation. The EdU concentration should match the stimulation strength, requiring higher concentrations to efficiently track DNA replication detection during increased cellular division. Day 5 was the optimal read‐out day for the EdU incorporation assay. We then combined the VPD450 dye dilution and EdU incorporation assays. As a proof of principle, we stimulated PBMCs from healthy donors with tetanus toxoid to assess antigen‐specific T‐cell responses. Additionally, we demonstrated the assay's application in drug research by evaluating proliferation in a mixed lymphocyte reaction with abatacept, an agonistic anti‐CTLA‐4 antibody. This combined approach offers qualitative insights into T‐cell proliferation kinetics, beneficial for assessing novel vaccine efficiency or for designing new treatments targeting T cell proliferation, such as in autoimmune settings.

01 Feb 2025·Cancer research communications

Dynamic Tracking of Tumor Microenvironment Modulation Using Kaede Photoconvertible Transgenic Mice Unveils New Biological Properties of Viral Immunotherapy

Article

Author: Richardson, Erin ; Li, Zhi ; Withers, David R. ; Tak, Paul P. ; Willis, Claire ; Idris, Suaad ; Barone, Francesca ; Guo, Qiuchen ; Diers, Anne R.

Abstract:

CAN-2409 is a replication-defective adenovirus that delivers the herpes simplex virus–thymidine kinase gene to infected cells. Intratumoral administration of CAN-2409, followed by prodrug, results in the formation of a toxic metabolite able to induce immunogenic cell death, exposure of tumor-associated antigens, and activation of local and systemic immune responses. We used a dynamic labeling model with MC38 tumor cells implanted in photoconvertible Kaede mice. Violet light was used to label the tumor microenvironment (TME), distinguishing retained versus newly entering cells and allowing real-time monitoring of immune compartment changes within tumors. Administration of CAN-2409 + prodrug led to control of tumor growth and significantly increased effector CD8+ T-cell responses. Photolabeling of the TME revealed that rather than enhancing recruitment of T cells to the tumor, CAN-2409 altered the TME whereby newly entering and retained CD8+ T cells were significantly more proliferative. CAN-2409 supported reinvigoration of tumor-associated antigen–specific CD8+ T cells and expansion of regulatory T cells of an altered phenotype. Moreover, the combination of CAN-2409 + prodrug and anti–CTLA-4 antibody treatment further improved control of tumor growth, in part by the enhanced CD8+ T-cell–mediated effector function and diminished regulatory T cell–mediated immunosuppression. Collectively, these data defined at least two temporally distinct pathways underpinning the mechanism of action of CAN-2409 that overcome cell exhaustion and decrease immune suppression. The results also support the rationale for future clinical trials of CAN-2409 treatment combined with anti–CTLA-4 antibody therapy.

Significance::

This study utilized a novel photoconvertible mouse tumor model to track immune cell trafficking upon treatment with an investigational viral immunotherapy (CAN-2409), revealing enhanced T-cell responses after viral immunotherapy associated with local proliferation of T cells within tumors that could further enhance antitumor efficacy in combination with immune checkpoint inhibitors. These findings define temporally and spatially distinct interactions of immune cells that could be harnessed by novel therapeutics.

10 Jan 2025·European Thyroid Journal

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors

Review

Author: Yabe, Daisuke ; Yamauchi, Ichiro

Immune checkpoint inhibitors (ICIs) frequently cause immune-related adverse events (irAEs), with thyroid irAEs being the most common endocrine-related irAEs. The incidence of overt thyroid irAEs was in the range of 8.9–22.2% in real-world settings, typically triggered by antibodies against PD-1 and PD-L1 and rarely by anti-CTLA-4 antibodies alone. The representative clinical course involves biphasic changes in thyroid function: transient thyrotoxicosis and subsequent persistent hypothyroidism. The identified risk factors for thyroid irAEs include the presence of thyroid autoantibodies, thyroid uptake on 18F-FDG-PET, prior use of tyrosine kinase inhibitors (TKIs), high BMI and high thyroid-stimulating hormone levels. There is evidence that overt thyroid irAEs are associated with good prognosis, at least in non-small cell lung cancer. Although the clinical features have been well clarified, the management strategies require further refinement. Routine monitoring of thyroid function every 4–6 weeks during ICI therapy is recommended for early detection of thyroid irAEs. While thyrotoxicosis generally requires observation only, hypothyroidism should be promptly treated with levothyroxine replacement. Continuation of ICI therapy is typically feasible in patients with thyroid irAEs, provided their overall health remains stable. However, these strategies were largely based on clinical experience with monotherapy. As combination ICI therapies have been developed as first-line treatments, antitumor agents may modify the clinical features of thyroid irAEs. For example, cytotoxic agents can delay the onset of thyroid irAEs, while TKIs are often linked to early-onset hypothyroidism, independent of ICI use. Given the increasing diversity and complexity of cancer immunotherapy, it is essential to vigilantly screen for thyroid irAEs.

268

News (Medical) associated with Botensilimab

12 Feb 2025

·www.businesswire.com

Agenus’ BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

LEXINGTON, Mass.--( BUSINESS WIRE )--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that BOT/BAL will be featured in two presentations at the upcoming American Association for Cancer Research (AACR) IO Annual Meeting that will take place on February 23-26 in Los Angeles, California. An oral presentation will highlight interim data from the ongoing Phase 2 study of botensilimab and balstilimab (BOT/BAL) in combination with MiNK Therapeutics’ iNKT cell therapy, AgenT-797, in patients with refractory (2L+) gastric cancer ( NCT06251973 ). A Trial-in-Progress (TiP) poster will feature data from the ongoing Phase 1/2 study of BOT/BAL in first-line MSS colorectal cancer ( NCT05627635 ). Presentation Details: Abstract Title: First-line botensilimab and balstilimab optimization in microsatellite stable colorectal cancer (MSS-CRC) without liver metastasis (BBOpCo) Session : Poster Session A Session Date and Time: Monday, February 24 th , 1:45-4:45 p.m. PST Abstract Title: Biomarker analysis from phase 2 study of AgenT-797 (invariant natural killer T-cells), botensilimab (a Fc-enhanced CTLA-4 Inhibitor) with balstilimab (anti-PD-1) in PD-1 refractory gastroesophageal cancer (GEC) Session : Proffered Papers, Session 2 Session Date and Time: Tuesday, February 25 th , 1:00-1:45 p.m. PST About Agenus Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline of immunological agents. The company was founded in 1994 with a mission to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations footprint. Agenus is headquartered in Lexington, MA. For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media channels. About Botensilimab (BOT) Botensilimab (BOT) is a human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti-tumor immune responses. Its novel design leverages mechanisms of action to extend immunotherapy benefits to “cold” tumors which generally respond poorly to standard of care or are refractory to conventional PD-1/CTLA-4 therapies and investigational therapies. Approximately 1,100 patients have been treated with botensilimab and/or balstilimab in phase 1 and phase 2 clinical trials. Botensilimab alone, or in combination with Agenus’ investigational PD-1 antibody, balstilimab, has shown clinical responses across nine metastatic, late-line cancers. For more information about botensilimab trials, visit www.clinicaltrials.gov with the identifiers NCT03860272, NCT05608044, NCT05630183, and NCT05529316. About Balstilimab (BAL) Balstilimab is a novel, fully human monoclonal immunoglobulin G4 (IgG4) designed to block PD-1 (programmed cell death protein 1) from interacting with its ligands PD-L1 and PD-L2. Botensilimab augments immune responses across a wide range of tumor types by priming and activating T cells, downregulating intratumoral regulatory T cells, activating myeloid cells and inducing long-term memory responses. About AgenT-797 AgenT-797 is an allogeneic invariant natural killer T (iNKT) cell therapy, leveraging a unique innate immune cell type that serves as a master regulator of both innate and adaptive immunity. iNKTs combine the cytotoxic capabilities of natural killer (NK) cells with the adaptive memory of T cells, enabling them to elicit a broad range of immune responses in a pathogen-agnostic manner. AgenT-797 is a scalable, “off-the-shelf” cell therapy product, manufactured by MiNK Therapeutics in Lexington, MA, to deliver transformative treatment solutions to patients. Forward-Looking Statements This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the federal securities laws, including statements regarding its botensilimab and balstilimab programs, expected regulatory timelines and filings, and any other statements containing the words "may," "believes," "expects," "anticipates," "hopes," "intends," "plans," "forecasts," "estimates," "will," “establish,” “potential,” “superiority,” “best in class,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the factors described under the Risk Factors section of our most recent Annual Report on Form 10-K for 2023, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Agenus cautions investors not to place considerable reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this press release, and Agenus undertakes no obligation to update or revise the statements, other than to the extent required by law. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.

Phase 2ImmunotherapyAACRCell TherapyPhase 1

28 Jan 2025

·www.mobihealthnews.com

Grey Matter Neurosciences secures $14M for Alzheimer's Disease

Neurotechnology company, Grey Matter Neurosciences, announced it secured $14 million in seed financing, which will be used to develop an ultrasound headset for individuals with Alzheimer's disease and test that device in clinical trials. The financing was led by the Wittington Innovation Fund, with participation from Toronto Innovation Acceleration Partners, Ontario Brain Institute and Ontario's Life Sciences Innovation Fund. The company also announced that it has licensed advanced focused ultrasound technology developed at Sunnybrook Research Institute. WHAT IT DOES Grey Matter Neurosciences develops portable ultrasound helmet technology aimed at empowering seniors to restore brain function. The company offers focused ultrasound technology for neuromodulation, with the aim of allowing seniors with Alzheimer's disease to experience enhanced brain-function recovery. In a statement, the company said its offerings are based on transcranial focused-ultrasound technology, which was invented by Kullervo Hynynen at Sunnybrook Research Institute. The seed funding will support advanced research on focused ultrasound neuromodulation. The company will construct an ultrasound headset for Alzheimer's patients and perform clinical trials to demonstrate the safety and feasibility of the technology. Investigators will also analyze the ability of the transcranial focused-ultrasound device to sustainably improve cognitive performance, including memory. "Generally speaking, there are no marketed therapies that can significantly and sustainably enhance cognitive function in individuals with dementia," Jeffrey Coull, founder and CEO of Grey Matter, said in a statement. "I believe that our technology, which can reach the deepest recesses of the brain that control memory and learning, holds massive potential to boost cognition and, more generally, revolutionize how Alzheimer's and other diseases of the brain are treated." The company also announced that Jim Orlando, managing partner of Wittington Ventures; Lara O'Donnell, executive director of the Weston Family Foundation; and Andy Smith, president and CEO of Sunnybrook Health Sciences Centre would join the company's board of directors. In addition, Parimal Nathwani, president and CEO of Toronto Innovation Acceleration Partners, will serve as a board observer. MARKET SNAPSHOT Other companies in this space include Soterix Medical, which offers stimulation and synergistic monitoring technologies. In 2024, the company received 510(k) clearance from the FDA for its Intraoperative Neurophysiologic Monitoring (IOM) system. MEGA-IOM provides integrated control of the central and peripheral nervous systems to reduce postoperative risk and improve surgical outcomes. Also in 2024, CNS disease-focused NaviFUS entered into an agreement with Bracco, a company that markets ultrasound imaging agents, to enhance the NaviFUS system's capability to open the blood-brain barrier for the treatment of brain cancers and neurological diseases. That same year, Sonic Concepts, a noninvasive therapeutic ultrasound platform, acquired the exclusive worldwide perpetual license for ultrasound neuromodulation patents from private neurotechnology company IST. The portfolio contains inventions and patents from Arizona State University that include discoveries of using low-intensity ultrasound for neuromodulation. Carthera, a clinical-stage medtech company, focuses on developing innovative ultrasound-based medical devices to treat a wide range of brain disorders. SonoCloud is a medical device developed by Carthera that emits ultrasound to temporarily increase the permeability of the blood vessels in the brain to improve the delivery of therapeutic molecules. In 2024, Carthera launched a Phase 2a clinical trial. The Northwestern University-sponsored trial used Carthera’s SonoCloud-9 device with Agenus’ checkpoint inhibitors balstilimab and botensilimab in patients with newly diagnosed glioblastoma (GBM) who have completed radiotherapy.

Phase 2License out/in

25 Jan 2025

·endpts.com

Agenus continues partnership talks for anti-CTLA-4 combo with new Phase 2 data

Five months after the FDA blocked its plans for accelerated approval, Agenus is moving ahead with discussions with potential pharma partners to chart a more conventional registrational path for its anti-CTLA-4 drug combo that has new Phase 2 data in advanced colorectal cancer. There are a variety of different partnership proposals on the table, with some focused on co-developing and others on financing, Agenus chief medical officer Steven O’Day told Endpoints News in an interview. “These negotiations are active — they’re moving forward,” he said. During its second-quarter earnings call last year, the company already indicated that it was looking for partnerships for botensilimab, which is combined with its PD-1 candidate balstilimab (BOT/BAL). According to data presented Saturday at the ASCO Gastrointestinal Cancers Symposium in San Francisco, the biotech’s 75 mg dose of botensilimab combined with balstilimab achieved a 19% objective response rate in patients with refractory microsatellite stable metastatic colorectal cancer that had spread to certain body parts but not the liver. This compares well with an ORR of zero for the control arm, which featured standard-of-care: Bayer’s Stivarga or Taiho Pharmaceutical’s Lonsurf. The 75 mg treatment cohort also achieved a 55% disease control rate. This means that more than half the patients treated with the combo were no longer progressing, O’Day said. Hello, Traci Lang You’re an essential part of the biopharma world. Share your voice on this important question to help shape our understanding of the industry. Can you help us out? Hello, Traci Lang You’re an essential part of the biopharma world. Share your voice on this important question to help shape our understanding of the industry. Can you help us out? The company has regulatory “alignment” to move forward with the 75 mg regimen in a Phase 3 trial with survival as a primary endpoint, he added. In July 2024, the FDA advised Agenus against pursuing accelerated approval for BOT/BAL based on data from previous Phase 1 and 2 studies in relapsed or refractory non-microsatellite instability-high colorectal cancer. The agency said that response rates in this population have not always translated to survival outcomes, adding it wanted to see a definitive survival study. Now that a Phase 3 is in the cards, Agenus has several options as to the specific subset of colorectal cancer patients it advances in, O’Day said. Other than the late-line setting, “we can also move into earlier-line metastatic colon and neoadjuvant” disease, he said. The company shared results from various BOT/BAL-based regimens in these other settings at ASCO GI. “But clearly the Phase 3 refractory [setting] is the most set up in terms of the work that’s been done with dose and contribution and a large database,” O’Day said. Agenus is no stranger to regulatory struggles. In 2021, the drugmaker withdrew its accelerated BLA for balstilimab in second-line cervical cancer shortly after the FDA cleared Merck’s Keytruda for full approval in the same setting. In August 2024, Bristol Myers Squibb turned its back on a pact with Agenus for a bispecific anti-TIGIT drug that featured more than $1 billion in potential milestones. Last month, the biotech launched a biologics manufacturing business to help it make money. In November, it had just $44.8 million in consolidated cash.

Phase 3Clinical ResultAccelerated ApprovalPhase 2Phase 1

100 Deals associated with Botensilimab

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced cancer	Phase 3	FR	Agenus, Inc.	15 Oct 2024
stomach adenocarcinoma	Phase 3	FR	Agenus, Inc.	15 Oct 2024
Mismatch repair-deficient Solid Tumors	Phase 3	NL	Agenus, Inc.	29 Jan 2024
Solid tumor	Phase 3	NL	Agenus, Inc.	29 Jan 2024
Microsatellite Stable Rectal Carcinoma	Phase 2	US	Agenus, Inc.	20 Feb 2025
Adenocarcinoma of large intestine	Phase 2	US	National Cancer Institute	01 Nov 2024
Advanced Colorectal Adenocarcinoma	Phase 2	US	National Cancer Institute	01 Nov 2024
Locally Advanced Rectal Carcinoma	Phase 2	US	National Cancer Institute	01 Nov 2024
Metastatic colon cancer	Phase 2	US	National Cancer Institute	01 Nov 2024
Metastatic Microsatellite Stable Colorectal Carcinoma	Phase 2	US	National Cancer Institute	01 Nov 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03860272 (Phase I study, Pubmed \| J Clin Oncol)	Phase 1	tumor mutational burden \| cytokines \| PD-L1 expression	64	Botensilimab 1 mg/kg + Balstilimab 3 mg/kg	xhbymbwrol(zeojrotcnk) = ogoufixsbj kqrkjqtkij (liflnlqksa, 9.6 - 32.5) View more	Positive	27 Jan 2025
				Botensilimab 2 mg/kg + Balstilimab 3 mg/kg	xhbymbwrol(zeojrotcnk) = uacqqnpgua kqrkjqtkij (liflnlqksa, 9.7 - 53.5)
NCT05571293 (NEST, ASCO_GI2025)	Phase 2	Microsatellite instability-high colorectal cancer Neoadjuvant pMMR \| dMMR \| MSI-H ... View more	-	Neoadjuvant BOT 75 mg/m2	doampjjlem(ievprpamja) = grade 2 diarrhea/colitis occurred in 8% yijyojcwza (nbzpwvgvpx ) View more	Positive	23 Jan 2025
				Neoadjuvant BAL 240 mg/m2
UNICORN (ASCO_GI2025)	Phase 2	Mismatch repair-deficient Colonic Cancer Neoadjuvant pMMR \| dMMR	56	Botensilimab 1 mg/kg	grioeouwoc(tuexikzmpp) = amhgqseaze ncniuzhhka (ailvfthnhs ) View more	Positive	23 Jan 2025
				Botensilimab 1 mg/kg + Balstilimab 3 mg/kg	dkuzllbmdf(zlnoqtovbw) = yshxnrszts iigluvlpjz (ntxkytcxcw ) View more
NCT05608044 (ASCO_GI2025)	Phase 2	Metastatic Microsatellite Stable Colorectal Carcinoma MSS \| pMMR \| KRAS mutant ... View more	234	Botensilimab 75 mg Q6W	znjjtdlqiw(kjvdygkslm) = zvjyuvewqr oeaoyfvqhb (xhvlvhggut ) View more	Positive	23 Jan 2025
				Botensilimab 150 mg Q6W	znjjtdlqiw(kjvdygkslm) = bbvntzhlbq oeaoyfvqhb (xhvlvhggut ) View more
NCT05627635 (ASCO_GI2025)	Phase 1	Microsatellite Stable Colorectal Carcinoma MSS	14	Folinic acid, fluorouracil, oxaliplatin, bevacizumab, botensilimab, balstilimab (FOLFOX-3B)	avrybrnrwk(tvcydskert) = one pt at DL1 with transient G3 AST/ALT elevation and transient G2 colitis (resolved with steroids and infliximab), one pt at DL1 with G2 hypothyroidism and one patient at DL2 with G2 hyperthyroidism mtzxaaejor (xshbuyliyt ) View more	Positive	23 Jan 2025
NCT05864534 (Pubmed \| Neuro Oncol)	Phase 2	Glioma	-	FcE-aCTLA-4	elwvuigviu(ymvdjtuyzq) = dxfmthwhbr nvsvlmtlcb (iwwumbhbrx )	-	04 Nov 2024
NCT03860272 (ESMO2024) Manual	Phase 1	Sarcoma	63	Botensilimab balstilimab	btfnolltyv(nuqukqczwz) = Any grade immune-mediated adverse events (AEs) occurred in 52% of pts, most commonly, diarrhea/colitis (38%; 11% Gr3). No Gr4 or 5 treatment-related AEs occurred. rsvocilqtt (tzefaywrxl ) View more	Positive	13 Sep 2024
NCT03860272 (NEST-1, Biospace) Manual	Phase 1/2	Colonic Cancer Neoadjuvant Microsatellite Stable (MSS) \| MSI-High	20	botensilimab with balstilimab + botensilimabal dosbalstilimablimab (MSS + NEST-1 cohort)	yvxnxhrexw(qdfszzjoiv) = fdjaalzvnf ufqjxxtwuo (ldgwkkslqi ) View more	Positive	28 Jul 2024
				botensilimab with balstbalstilimab + botensilimabal dose of balstilimab (MSI-H + NEST-1 cohort)	yvxnxhrexw(qdfszzjoiv) = vodlbwawhg ufqjxxtwuo (ldgwkkslqi ) View more
BusinessWire Manual	Phase 2	Metastatic Microsatellite Stable Colorectal Carcinoma	-	Botensilimab 75mg + Balstilimab 240mg	vnoxvomitq(uvpblzwnme) = algeobuaii awxexdwaco (swtwgyavic, 10.4 - 31.4) View more	Positive	18 Jul 2024
				Botensilimab 150mg + Balstilimab 240mg	vnoxvomitq(uvpblzwnme) = sltpbcewij awxexdwaco (swtwgyavic, 2.7 - 18.1)
Biospace Manual	Phase 1	Metastatic Microsatellite Stable Colorectal Carcinoma Microsatellite Stable (MSS)	77	botensilimab + balstilimab	skcvvockch(qlxlbxppva) = rqllpikqmh vvqqxirqxl (kiztnsyvtm ) View more	Positive	13 Jun 2024

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Botensilimab

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation